I n the last 20 years, screening for colorectal cancer (CRC) has undergone a paradigm shift once its prevention potential was recognized. It has progressed from parochial ad hoc opportunistic activities, led by clinical champions, to a structured, organized public health priority tailored to specific health-care environments in population-based settings. Indeed, 2018 marks the 20th anniversary of a global initiative established by the Organisation Mondiale d'Endoscopie Digestive (OMED, now the World Endoscopy Organization [WEO] ) that was charged "to promote the international implementation of CRC screening programs."
1 This commentary evaluates this remarkable health care transformation and the reasons for its success.
CRC is a major worldwide public health issue ranked in the top ten diseases for health burden by the World Bank. 2 Although there is wide geographic variation in CRC incidence (Figure 1 ), 3 being higher in developed than developing countries, its incidence is increasing in those with growing affluence (Supplementary Figure 1) . 4 It is predicted that, by 2040, the number of cases will have risen from 1.850 million now to 3.093 million in 2040 (http://gco.iarc.fr/ tomorrow/home). This huge burden remains a challenge despite the expert consensus view that CRC is one of the most preventable cancers. 5, 6 Secondary prevention is effective in decreasing the incidence and mortality without regard to lifestyle changes.
Establishment of a Global Expert Network
Five decades ago, the World Health Organization (WHO) developed criteria for a public health approach to screening providing that evidence and health burden justified it and it was feasible. 7 Two decades ago the evidence emerged. Guaiac-based fecal occult blood tests (gFOBT) had been proven to reduce mortality through early detection of neoplastic lesions. [8] [9] [10] [11] Colonoscopy had been shown to decrease incidence and CRC mortality after polypectomy, 12 subsequently supported by flexible sigmoidoscopic screening. [13] [14] [15] [16] [17] Fecal immunochemical tests for hemoglobin 18 (fecal immunochemical testing [FIT] ) had been shown to decrease CRC mortality, 19 and then promised to replace gFOBT. 20 Guidelines for screening had emerged even before definitive supporting evidence in Australia 21 and soon after in the United States. 22, 23 It was in this environment in 1997 that colleagues, led by Massimo Crespi and Glaciomar Machado, proposed the establishment of a global network. OMED endorsed this approach by convening a CRC Screening Committee (SC) to provide "a forum for international interaction" and "promote innovation" and collaboration "with fellow professional associations." 1, 24 It was felt that this effort would facilitate translation of the evidence into clinical practice and reduce the CRC burden. The initial committee of 12 members (see Acknowledgements) first met in Vienna in 1998, under the chairmanship of Paul Rozen. 24 
Style of the Network
From the outset, the committee did not deviate from its mission. Where evidence was inadequate or new solutions necessary, committee members conceptualized, discovered, and critically evaluated likely solutions. The meeting style adopted was of short, focused talks and uninhibited critical discussion that included early and midcareer colleagues. An atmosphere of collaboration and mutual respect prevailed, thus stimulating innovation and a thirst for understanding. Members lead or contributed to the development of guidelines; interacted with policymakers, funders, and governments; and debated challenging dichotomies, which included: 
What Emerged From This Network
The global network grew from 12 individuals from 8 countries in 1998 to 1180 members from 78 countries in 2018 (Supplementary Figure 2) . Graeme Young became Chair in 2005 and Linda Rabeneck in 2013. Network activities grew from 1 to 4 regional meetings annually, led by regional chairs, held in Europe, Asia-Pacific, and North and South America. Annual meeting attendance increased exponentially (Supplementary Figure 2) .
Although initially championed by gastrointestinal experts promoting the adoption of an effective test with little involvement of public health professionals, it grew to be a truly multidisciplinary professional network, including gastroenterologists, epidemiologists, surgeons, bench scientists, pathologists, imaging specialists, public health experts, behavioral scientists, sociologists, nurses, and statisticians, as well as representatives from governmental, patient, and cancer organizations. The strategy that emerged-provision of an effective evidence-based screening test in an organized, high quality, tightly monitored, structured program directed at an informed and responsive population, that was feasible within the relevant health care environment-reflected the WHO principles for screening 7 and the International Agency for Research on Cancer (IARC) definition of an organized program. 25 It took time to engage public health experts, with their expertise and focus on sustainable, cost-effective, population-based interventions. Some saw CRC screening to be more challenging than breast and cervical cancer screening, in part owing to complexity of the screening program, multiplicity of risk groups needing personalized approaches, multiple test options, high-volume invasive diagnostic testing (colonoscopy), and risks inherent in removal of the precancer lesions. CRC screening was seen as a multiphase organized process ( Figure 2 ) in which failure in any step would compromise mortality reduction. 25, 26 Monitoring of each phase for service quality, especially colonoscopy withdrawal time and adenoma detection rate, 27 was important to population benefit and credibility with funders, policy makers, and the public. 28 The wide variation in health service environments meant that no single program design could be applied globally.
By sharing experiences and providing practical examples, new standards and expectations were developed. Those new to screening implementation were able to scrutinize earlier experiences, choose the right protocol, process and test for their environment, accept the challenge to do it even better, and avoid the pitfalls others encountered. Members were energized and became powerful advocates for CRC screening in their respective environments.
To address issues that were perceived to be either neglected or challenging, Expert Working Groups were established in 2012 and 22 peerreviewed consensus documents have so far emerged from these (see www. worldendo.org/about-us/committees/ colorectal-cancer-screening/ccs-testpage2-level4/).
Industry involvement was encouraged with a beneficial impact on technology development. Industry was exposed to the issues facing the public and health professionals. As a result, major advances were made in the steps leading to diagnosis. For example, qualitative gFOBTs have been replaced by quantitative FIT, 6, 20, 29 and the introduction of molecular tests presents new opportunities. 30 The detection of neoplasia was seen in a public health framework as being the product of access, participation, and test sensitivity, together with program principles of feasibility, acceptability, and equity. The test options for CRC screening differ greatly in terms of access, simplicity, acceptability, and cost; studies now show that these differences affect participation. For example, better participation is achieved with FIT than with gFOBT. 31 Increasing awareness of the benefit of screening 32 and developing processes that facilitate easy participation 31 all serve to improve screening.
Global Explosion in Screening Activities
The nature and coverage of CRC screening increased across the globe (Table 1) in these 2 decades. 1, 24, 29, [33] [34] [35] [36] Given the need to be feasible within the local health-care environment, 2 types of public health, WHO and IARC principle-consistent programs emerged (in contrast to ad hoc opportunistic screening): population-based organized screening (PBOS) and structured opportunistic screening (SOS). 6, 25, 34 PBOS has an explicit policy; a team responsible for organization, print & web 4C=FPO Figure 1 .Current status and trends in the worldwide incidence of colorectal cancer. Geographical variation in the estimated age-standardized incidence rates of colorectal cancer (both sexes, ages 0-85 years). 3 The age-standardized CRC incidence rate for Hong Kong and Taiwan invitation, and health care; and processes to monitor and improve quality and outcomes. In 1999, the only PBOS (including pilots) were in Japan (which started in 1992), Uruguay, and Italy. 24 By 2002, Australia, Taiwan, France, and the UK had started pilot programs to assess their feasibility.
1 By 2015, 22 countries had commenced and by 2018 this has grown to 30 countries with an additional 19 in the pilot phase (Supplementary Figure 3) . 36 Almost all countries with a PBOS have chosen 2-step screening with FIT as the first step (Table 1) . Only Italy and the UK now include flexible sigmoidoscopy as an initial screening test and few have adopted colonoscopy. Insufficient endoscopy workforce capacity and skill is the major factor, and for colonoscopy the lack of evidence from randomized, controlled trials (although these are now underway) and equity of access.
SOS had already gathered momentum in the United States in 1999, with Germany just underway (Table 1) . 1, 24 By 2018, this had grown to nine countries promoting SOS (Supplementary Figure 3) . Colonoscopy is somewhat more likely as the screening test in SOS. In reality, many countries have some degree of ad hoc opportunistic screening that may run in parallel with PBOS, depending on the health care environment and its funding.
All but 2 of the 30 countries with an age-standardized CRC incidence rate (0-85 years) of 30 per 100,000 3 have PBOS or SOS underway (data not shown). Thirty-six with an incidence rate of 25/100,000 are beyond the pilot phase (data not shown). Pilot screening programs (Table 1 provides a concept explanation) are highly desirable before committing to PBOS. Beside determining feasibility, they enable calculation of cost effectiveness based on actual local observations rather than modelling. Such programs have proved useful in convincing authorities to proceed in many countries, but as is evident in Supplementary   Figure 3 and Table 1 , some jurisdictions are slow in advancing from pilot to PBOS.
Screening Programs Are Heterogeneous
Although the highest level of evidence (multiple randomized, controlled trials) supports the implementation of FOBT screening for the general population 50 years, [8] [9] [10] many countries have constrained their PBOS programs in various ways so as to manage the resultant colonoscopy workload in an equitable, timely, and high-quality manner. For instance, countries such as England and Australia have initially constrained the age range of those offered screening while settings such as the Netherlands and Scotland have tailored the sensitivity of FIT (using a higher quantitative FIT threshold) to reduce colonoscopy workloads. Although many countries have a PBOS in place, most have the scope for further adjusting FIT thresholds for positivity (using quantitative FIT), increasing coverage, and improving participation rates and/or colonoscopy quality.
Because CRC screening is a multiphase process (Figure 2) 26 that must be feasible within a particular health care environment, remarkable diversity in processes, summarized in Table 2 , is seen across jurisdictions.
The New Screening Tools
The impact of gFOBTs on CRC mortality in the randomized, controlled trials was modest [8] [9] [10] because they missed cancers and many adenomas. 37 Quantitative FIT has proved superior to gFOBT: increased participation rates (single stool sample and simpler collection technique), automated analyzer for objective and consistent measurement, increased sensitivity for cancer and adenomas, no significant drug or dietary interference, and an objective adjustable end point that can be tailored to available colonoscopy capacity and expectations of test performance. 20 FIT eventually replaced gFOBT and became a game-changer for 2-step screening. 237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295   296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353 38 and in blood. Blood tests for circulating tumorderived DNA are emerging, but lack sensitivity for adenomas.
39,40 The multitarget stool test based on an algorithm including stool hemoglobin and certain genetic events (somatic and epigenetic) is the most sensitive of the available noninvasive screening tests. 30 
What Comes Next for Screening?
Despite the explosion in screening programs, there is much more to be done as emphasized in a recent report from Asia. 41 Commitment to an adequate infrastructure ( Figure 2 ) can be lacking. Jurisdictions vary greatly in their commitment to training the workforce needed to conduct a full program. The desired outcomes of a program must be set, every important measurable event monitored and actual performance relative to goals reported on a regular basis. Monitoring identifies underperforming areas and facilitates improvement. Health system data access including cancer registries are vital infrastructure components.
Population reach remains a concern for all countries. Reported participation uncommonly exceeds 65% and can be as low as 9%. 29, 36 Inequities are frequently seen according to age, sex, education, ethnicity, language, and socioeconomic status. Obstacles to participation need to be addressed by considering lessons learned from programs with higher participation. Solutions are required for failure to progress to diagnostic colonoscopy after a positive test in 2-step screening with uptake in most programs of <90%.
The quality of colonoscopy is emerging as a fundamental challenge and attention to quality measures will improve screening. 27 The processes for monitoring performance and taking remedial action are not always well-defined and tend to be underresourced. Image-enhanced endoscopic methods are being developed for difficult-to-detect lesions such as sessile serrated adenoma, but have not Ad hoc opportunistic screening occurs in many countries, sometimes as the only form of screening, but also as an alternative and alongside organized programs. This ad hoc activity is generally practitioner based and is not included in the category termed SOS, even when supported by professional guidelines. a Nature of program: Definitions: Population-based organized screening (PBOS): The definition is adapted from that applied by the International Agency for Research on Cancer. 25 These programs aim to operate at a population level and target an "agedefined" population. They follow an explicit policy, with structures responsible for organization, including invitation, primary (eg, FIT) and secondary testing (eg, colonoscopy), service monitoring including outcomes and quality assurance. Populationbased pilot programs: These population programs are undertaken on a limited scope, usually at a regional level and with intent to roll out if successful. The usual goals are to test feasibility, test procedural options, gain experience and gain support for progressing to a PBOS program. Elements such as an explicit policy, structures responsible for organization, including invitation, primary (eg, FIT) and secondary testing (eg, colonoscopy), service monitoring including outcomes and a structure for quality assurance may not be fully determined or need testing. Structured Opportunistic screening (SOS): This is screening supported by official policy (not merely professional guidelines) with support at a public health level and by funders such that it aims to achieve extensive coverage of the target population. Attention to quality and monitoring of outcomes must be included. This does not include ad hoc opportunistic screening either in the absence of or outside an organized screening program that relies on recommendation from individual health-care providers or individual self-referral. Screening test is guaiac-based fecal occult blood testing. c Screening test is FIT. The rollout of PBOS programs from pilot to population program takes some years with variation between jurisdictions as to whether this is implemented locally, regionally, or nationally. For example, some pilot regions just continue as the early stage of a more wide-spread program. No effort has been made to identify whether programs are at an early or more mature stage except where they are formally transitioning from a pilot in which case they are identified as PBOS and marked " 473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531   532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589 proved to be superior to white light endoscopy in experienced hands. Two of the Expert Working Groups (Interval Cancers and Image-enhanced Endoscopy) have emphasized the importance of high-quality procedures to detect flat and/or sessile lesions so as to avoid interval cancers. 42 Greater personalization of screening that adjusts age to start screening, screening intervals, and choice of screening test according to an individual's risk would enable us to move on from the standardized somewhat impersonal approach characteristic of PBOS. Personalization is possible using data held by health care systems, but better access to such data at each phase together with processes to deal with privacy concerns will be needed. Age, sex, family history, diet, body mass index, lifestyle (including alcohol and smoking), ethnicity, socioeconomic history, genetic polymorphisms, past screening behavior, and colonoscopic investigations as well as past FIT stool concentration levels (even when negative), 43 can potentially be used to create algorithms and make decisions about when to screen, how often to screen, and whether to undertake 2-step or 1-step screening. This method is particularly attractive for resource-limited countries or those where subpopulations have widely differing risks. 44 Artificial intelligence might facilitate this process. Given the evidence for increasing CRC incidence at a younger age, consideration to expand the target age range is required.
45
Integration of research, whether basic, applied, or health delivery in nature is proving increasingly difficult as countries commit to mandated programs and monitored outcomes. Very few countries have structurally incorporated such research into their program and this is essential if we are to further improve delivery and fully evaluate potentially better tests. 46 Although huge gains in screening programs have been achieved, the SC continues to strive to conduct the By coordination through mandated screening process using approved dedicated screening colonoscopy facilities. By designated and accredited screening colonoscopists (physicians/internists/surgeons, nurses, technicians, etc). By "usual care" processes available to participants through their chosen accessible options. Note: Data reporting obligations and processes vary considerably between these options. Histopathology
By pathologists dedicated and accredited for CRC screening pathology (including regular audit review of service quality, quality assessment program for screening pathologists). By "usual care" processes available to colonoscopists. Monitored data and managed quality assurance
Monitoring might be by centralized computer monitoring of all service activities and results reported to it, especially for designated outcomes of interest. How this operates depends on data reporting obligations and processes in place. Monitoring of quality is often devolved to local facilities which might or might not be required to report regularly to a governing authority. Regional or national cancer registries are crucial measurement for impact. Note: Regular service audits and data review vary considerably between these options. Navigation between phases By centralized coordinating staff with real-time access to data and authority to manage processes such as notification of results and coordination of appointments (such as for colonoscopy). By "usual care" processes determined by choice of participant and according to advice from their chosen physicians.
Abbreviation: CRC, colorectal cancer. a Remarkable diversity is apparent regardless of whether the approach is as a population based organized screening program or structured organized screening.
necessary research and support appropriate translation into good evidencebased screening practice.
Conclusions
CRC screening is unique among cancer screening programs owing to its complexity, multiple test options that can be adapted to suit local circumstances, and capacity to detect and easily remove precancerous lesions and hence prevent the cancer.
Huge progress has been made in providing evidence and translating this into screening practice as demonstrated by the documented increase in organized programs. Screening programs that are feasible within the resources of the local health care environments and include explicit policy, monitoring of outcomes and mechanisms to achieve quality assurance-all essential WHO and IARC principles-are now widespread (Table 1) . 28, 34 It is remarkable to see the diverse ways in which such complex programs have been implemented across the globe and adapted to suit relevant circumstances (Table 2) . Despite the advances made, however, the provision of structured organized screening in most countries still falls short of what is justified by the evidence base 29, 33, 36, 41 and jurisdictions can be slow to commit to rolling out screening beyond pilots as demonstrated by the failure in some countries to move from pilots to expanded and organized programs.
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